Durect Corporation (DRRX) Shares are Up 22.92%

Durect Corporation (DRRX) : Traders are bullish on Durect Corporation (DRRX) as it has outperformed the S&P 500 by a margin of 30.55% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 22.17%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 22.92% in the last 1 week, and is up 39.37% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Durect Corporation (NASDAQ:DRRX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.66 and $1.55 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.82. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.77, notching a gain of 7.27% for the day. The total traded volume was 1,359,852 . The stock had closed at $1.65 on the previous day.


The stock has recorded a 20-day Moving Average of 34.09% and the 50-Day Moving Average is 39.04%. DURECT Corporation is up 28.26% in the last 3-month period. Year-to-Date the stock performance stands at -19.91%.

Durect Corporation is a specialty pharmaceutical company. The Company is focused on the development of pharmaceuticals based on its drug delivery technology platforms, chemical entities derived from its Epigenomic Regulator Program, and its engagement in drug development. Its research and development programs fall into one of two categories: Drug Delivery Programs, in which it applies its formulation and technologies to pharmaceutical ingredients, and New Chemical Entities derived from its Epigenomic Regulator Program, in which it discovers and develops molecules. It also manufactures and sells osmotic pumps and biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products. Its product pipeline consists of seven investigational drug candidates in clinical development: REMOXY (ORADUR-Oxycodone), POSIDUR (SABER-Bupivacaine), ELADUR (TRANSDUR-Bupivacaine), Relday, ORADUR-ADHD, ORADUR-Opioid and SABER-based ophthalmic.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *